Its potential to modulate metabolic and neuroprotective pathways offers hope for the development of new therapies that could improve the prognosis of patients with both diseases
found that GLP-1 receptor agonist use, compared with initiation of sodium-glucose cotransporter 2 (SGLT2) inhibitors, was associated with a lower risk of composite MALOs (aHR: 0.84, 95%CI: 0.74-0.94), including specifically lower occurrence of liver decompensation (aHR: 0.83) and all-cause mortality (aHR: 0.84) [56]
Oral formulations are also emerging, which may improve accessibility and further increase uptake
Atherosclerotic cardiovascular disease is caused by proinflammatory stimuli in the vascular endothelial cells and is associated with increased plasma levels of TNF- , IL-6, CRP, and circulating endotoxin (i.e., lipopolysaccharide (LPS)) [56, 57]
On 8th of May at the Translational Research Institute Australia, hear directly from researchers and industry experts who are shaping how early-stage discoveries progress towards translation
